Latest news with #Ultragenyx
Globe and Mail
14 hours ago
- Business
- Globe and Mail
RARE Investors Have Opportunity to Join Ultragenyx Pharmaceutical Inc. Fraud Investigation with the Schall Law Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ultragenyx Pharmaceutical Inc. ('Ultragenyx' or 'the Company') (NASDAQ: RARE) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Ultragenyx and development partner Mereo BioPharma Group plc issued a press release on July 9, 2025, to announce that the 'randomized, placebo-controlled Phase 3 portion of the Orbit study evaluating UX143 (setrusumab) in pediatric and young adult patients with osteogenesis imperfecta (OI) is progressing toward a final analysis." The Company disclosed that this final analysis would occur "around the end of the year." Based on this news, shares of Ultragenyx fell by more than 25.1% on the next day. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at or by email at bschall@ The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
Business Wire
14 hours ago
- Business
- Business Wire
RARE Investors Have Opportunity to Join Ultragenyx Pharmaceutical Inc. Fraud Investigation with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)-- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ultragenyx Pharmaceutical Inc. ('Ultragenyx' or 'the Company') (NASDAQ: RARE) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Ultragenyx and development partner Mereo BioPharma Group plc issued a press release on July 9, 2025, to announce that the 'randomized, placebo-controlled Phase 3 portion of the Orbit study evaluating UX143 (setrusumab) in pediatric and young adult patients with osteogenesis imperfecta (OI) is progressing toward a final analysis." The Company disclosed that this final analysis would occur "around the end of the year." Based on this news, shares of Ultragenyx fell by more than 25.1% on the next day. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at or by email at bschall@ The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
Yahoo
2 days ago
- Business
- Yahoo
Bank of America Securities Reiterated a Buy Rating on Ultragenyx Pharmaceutical (RARE)
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is one of the Best 52-Week Low Stocks to Buy According to Analysts. On July 14, Tazeen Ahmad from Bank of America Securities reiterated a Buy rating on Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), while lowering the price target from $80 to $79. The firm held its positive outlook even after the recent challenge from the FDA's complete response letter for UX111 in Sanfilippo syndrome. The CRL was focused on specific chemistry, manufacturing, and controls issues. Importantly, the clinical data for UX111 was not questioned; however, the approval is still achievable once the CMC issues are resolved. A research team in a laboratory peering through microscopes at a biologic product. The analyst noted that the company is responding quickly and plans to address the CMC concerns and resubmit its Biologics License Application in the coming months. The analyst is also optimistic due to Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) robust pipeline. The company has promising programs for conditions like osteogenesis imperfecta and Angelman syndrome. Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) develops treatments for rare and ultra-rare genetic diseases. They focus on biologics, small molecules, gene therapy, and nucleic acid products. While we acknowledge the potential of RARE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
3 days ago
- Business
- Yahoo
William Blair Maintains a Buy on Ultragenyx Pharmaceutical (RARE)
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is one of the best oversold NASDAQ stocks to buy now. On July 14, William Blair analyst Sami Corwin maintained a bullish stance on Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), giving it a Buy rating without a price target. A research team in a laboratory peering through microscopes at a biologic product. The analyst gave a positive rating based on the company's potential despite recent setbacks. Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) received a complete response letter from the FDA about UX111 for the treatment of Sanfilippo syndrome type A, citing concerns associated with chemistry, manufacturing, and controls (CMC). Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), however, maintains that the complications are not directly related to the quality of the product and are manageable. The analyst also reasoned that the FDA acknowledged the supportive nature of the clinical data for UX111, which includes biomarker evidence and strong neurodevelopmental outcomes. He stated that while the FDA requested updated clinical data, the existing data package does not have issues, which is a positive sign. Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) plans to promptly address the concerns put forth by the FDA and is planning resubmission and potential approval in 2026. Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) develops, acquires, and commercializes novel products to treat genetic diseases. Its product portfolio includes Crysvita, Mepsevii, Dojolvi, and Evkeeza. While we acknowledge the potential of RARE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
6 days ago
- Business
- Yahoo
Ultragenyx (RARE) Falls 26% as New Treatment Fails to Get FDA Green Light
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is one of the Ultragenyx fell by 26.05 percent week-on-week as investor sentiment was largely dragged down by the Food and Drug Administration's (FDA) rejection of its biologics license application (BLA) for its UX111 (ABO-102) treatment. In a regulatory filing, Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) said that the FDA requested additional information and improvements in relation to certain chemistry, manufacturing, and controls (CMC) aspects. It noted that the observations were not related to product quality concerns product, adding that many of the issues have already been addressed. UX111 was developed to treat a common type of Sanfilippo syndrome, a group of genetic conditions that begin in early childhood and causes severe brain damage and early death. A research team in a laboratory peering through microscopes at a biologic product. The treatment involves managing symptoms, as there are currently no approved disease-modifying medicines. Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) said it plans to resubmit updated clinical data from current patients after resolving the FDA's concerns. A new review could take another six months upon resubmission of a revised BLA application. While we acknowledge the potential of RARE as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
